X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PANACEA BIOTECH - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PANACEA BIOTECH ABBOTT INDIA/
PANACEA BIOTECH
 
P/E (TTM) x 42.5 176.4 24.1% View Chart
P/BV x 10.6 3.9 271.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   PANACEA BIOTECH
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
PANACEA BIOTECH
Mar-14
ABBOTT INDIA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs6,015149 4,045.1%   
Low Rs3,70782 4,504.3%   
Sales per share (Unadj.) Rs1,236.984.1 1,470.0%  
Earnings per share (Unadj.) Rs122.2-18.3 -667.4%  
Cash flow per share (Unadj.) Rs129.0-6.7 -1,925.3%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.283.7 622.7%  
Shares outstanding (eoy) m21.2561.25 34.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.91.4 286.3%   
Avg P/E ratio x39.8-6.3 -630.6%  
P/CF ratio (eoy) x37.7-17.2 -218.6%  
Price / Book Value ratio x9.31.4 675.9%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2967,074 1,460.1%   
No. of employees `0003.02.8 107.5%   
Total wages/salary Rs m3,3701,449 232.5%   
Avg. sales/employee Rs Th8,891.81,874.1 474.5%   
Avg. wages/employee Rs Th1,140.0527.0 216.3%   
Avg. net profit/employee Rs Th878.3-407.7 -215.4%   
INCOME DATA
Net Sales Rs m26,2845,154 510.0%  
Other income Rs m504100 505.4%   
Total revenues Rs m26,7895,254 509.9%   
Gross profit Rs m3,665-766 -478.3%  
Depreciation Rs m144711 20.3%   
Interest Rs m81,503 0.5%   
Profit before tax Rs m4,017-2,881 -139.5%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,42117 8,458.3%   
Profit after tax Rs m2,596-1,121 -231.5%  
Gross profit margin %13.9-14.9 -93.8%  
Effective tax rate %35.4-0.6 -6,064.8%   
Net profit margin %9.9-21.8 -45.4%  
BALANCE SHEET DATA
Current assets Rs m14,4463,810 379.1%   
Current liabilities Rs m4,7258,365 56.5%   
Net working cap to sales %37.0-88.4 -41.8%  
Current ratio x3.10.5 671.3%  
Inventory Days Days51156 33.0%  
Debtors Days Days2067 29.1%  
Net fixed assets Rs m1,11314,480 7.7%   
Share capital Rs m21361 346.7%   
"Free" reserves Rs m10,808903 1,196.8%   
Net worth Rs m11,0765,127 216.0%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m16,24119,433 83.6%  
Interest coverage x497.0-0.9 -54,224.0%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.60.3 610.3%   
Return on assets %16.02.0 816.4%  
Return on equity %23.4-21.9 -107.2%  
Return on capital %36.33.6 999.4%  
Exports to sales %0.624.5 2.5%   
Imports to sales %12.610.2 124.1%   
Exports (fob) Rs m1621,264 12.8%   
Imports (cif) Rs m3,322525 633.1%   
Fx inflow Rs m2681,539 17.4%   
Fx outflow Rs m3,927942 416.9%   
Net fx Rs m-3,659597 -612.8%   
CASH FLOW
From Operations Rs m2,514599 419.6%  
From Investments Rs m-800-438 182.6%  
From Financial Activity Rs m-803-303 265.3%  
Net Cashflow Rs m912-141 -645.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.6 1,316.7%  
FIIs % 0.1 1.3 7.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 23.6 72.5%  
Shareholders   18,270 10,259 178.1%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 16, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS